Lipoprotein(a) Foundation Highlights ACC Research Reinforcing the Significance of Lp(a) as a Genetic Risk Factor for Cardiovascular Disease

The Lipoprotein(a) Foundation is highlighting a number of studies reinforcing the significance of Lipoprotein(a), also known as Lp(a), as an independent, genetic risk factor for early cardiovascular disease being presented at the upcoming ACC.16, the 65^th Annual Scientific Session & Expo of the American College of Cardiology (ACC), April 2-4, 2016 in Chicago. The studies bolster a growing body of research that demonstrate the impact of elevated Lipoprotein(a) and present initial results of therapies under development to reduce Lp(a). The Foundation will be exhibiting at ACC.16 (Booth #22104).
According to the news:

A study recently published in the Journal of the American College of Cardiology(JACC) shows that the current cholesterol guidelines miss 8% of people who have a cardiovascular event whose only risk factor is high Lp(a).¹One in 5 people globally have inherited high Lp(a) – 63 million in the U.S.⁴ and Lp(a) is currently the strongest monogenetic risk factor for coronary heart disease and aortic stenosis.² Lp(a) concentrations can be measured by a simple blood test, but it is not included in most standard lipid panel tests that check cholesterol levels.¹ The Lipoprotein(a) Foundation recently issued anInfographic to raise awareness that a simple blood test could be the first step in preventing up to 120,000 cardiovascular events every year.

Click here to view the full press release.